Ibrutinib
Intervention2 papers4 findingsPubChem 24821094ChEBI 76612
- Humans2
Outcomes
3CAR T-cell expansion
upin cells1Low certainty
1 study
CAR T-cell expansion
upin cells1Low certainty
Ibrutinib increases CAR T-cell expansion in cells.
Cellsin an ibrutinib-resistant CLL model
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia · Blood · 24 Aug 2026
Senescence-associated secretory phenotype (SASP)
downin human cells1Low certainty
1 study
Senescence-associated secretory phenotype (SASP)
downin human cells1Low certainty
Ibrutinib inhibits senescence-associated secretory phenotype (SASP) in human cells.
Cellsin paired patient and direct-exposure assays
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia · Blood · 24 Aug 2026
Cellular senescence
downin human cells1Low certainty
1 study
Cellular senescence
downin human cells1Low certainty
Ibrutinib inhibits cellular senescence in human cells.
Cellsin paired patient and direct-exposure assays
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia · Blood · 24 Aug 2026
Associations
1Parkinson's disease
downin humans1RR 0.62Low certainty
1 study
Parkinson's disease
downin humans1RR 0.62Low certainty
Ibrutinib lowers the risk of Parkinson's disease in humans (RR = 0.62, 95% CI: 0.51-0.75).
Humansadjusted for age, sex, race, smoking, and healthcare utilization
Use of receptor and nonreceptor tyrosine kinase inhibitors and Parkinson disease risk · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 27 Aug 2026